Robert J. Maguire, Ph.D.
Director of Medicinal Chemistry
Dr. Robert J. Maguire is a seasoned medicinal chemist and leader in drug development, with over two decades of experience spanning early-stage discovery to clinical supply. As Director of Chemistry at Cybrexa Therapeutics, he has spearheaded the development of multiple peptide drug conjugates (PDCs), including CBX-12, currently in Phase 2 trials. His expertise extends across synthetic chemistry, route optimization, cGMP production, and external resource management, where he has successfully led collaborations with over 30 CROs and CDMOs.
Previously, Dr. Maguire held leadership roles at Pfizer, where he specialized in flow chemistry, process innovation, and medicinal chemistry for metabolic and oncology programs. His contributions have been instrumental in advancing novel drug candidates, optimizing synthetic routes, and reducing production costs. With a PhD in Synthetic Organic Chemistry and postdoctoral research experience at esteemed institutions, he continues to drive innovation in the pharmaceutical industry. Dr. Maguire is also committed to mentorship and community engagement, supporting educational initiatives such as Junior Achievement of Southeast Connecticut. His ability to blend scientific rigor with strategic leadership makes him a valuable asset in accelerating drug discovery and development.
SYNER-G | Bio Book
Robert J. Maguire, Ph.D.'s Recent Articles
Accelerating a Cytotoxic Peptide-Drug Conjugate to IND: A Medicinal Chemist’s Journey to IND with Syner-G BioPharma Group
As a medicinal chemist with experience in large pharmaceutical companies, I’ve spent my career designing and optimizing drug candidates. But when I was tasked with advancing a highly potent cytotoxic peptide-drug conjugate (PDC) toward IND submission, I found myself in…